SOHM, Inc., Announces Important Details of Its California Pharmaceutical Company Acquisition Expanding Manufacturing into the US Market
SOHM, Inc. (OTC PINK:SHMN) has announced a strategic acquisition of a Southern California pharmaceutical company, enhancing its manufacturing capabilities under FDA licensing. This acquisition allows SOHM to operate a cGMP-compliant contract manufacturing facility, previously operational since 2000, which currently produces 41,000 gallons of semi-solid, liquid, and topical products annually. The facility can expand to over 160,000 gallons per year, paving the way for increased revenues and profitability. The company aims to leverage this opportunity for growth in OTC, cosmeceuticals, and veterinary markets.
- Acquisition of an FDA licensed contract manufacturing facility to enhance production capabilities.
- Current production capacity of 41,000 gallons per year, with expansion potential to 160,000+ gallons.
- Access to over 300 proprietary formulations, opening new revenue streams.
- Strategic location in Southern California, facilitating distribution and growth in various healthcare segments.
- None.
Expanding SOHM, Inc's Pharmaceutical manufacturing capabilities under FDA licensing opens new opportunities for OTC, Cosmeceuticals, Veterinary, and Prescription Rx.
CHINO HILLS, CA / ACCESSWIRE / November 11, 2021 / SOHM, Inc. (OTC PINK:SHMN), a Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, released more information today regarding its long-awaited acquisition of a leading Southern California based pharmaceutical company.
Mr. Baron Night, President and CEO of SOHM Inc., said, "From the beginning, SOHM has worked hard to develop and deliver transformative and critically needed products to patients and consumers around the globe. Manufacturing under FDA licensing will enhance our efforts and our presence in the cosmeceutical market while spring boarding our pharmaceutical manufacturing programs which allow us to deliver more affordable products to more patients in need."
This step forward provides SOHM with a cGMP-compliant, FDA licensed contract manufacturing facility that has been in business since 2000. Expanding the core capabilities through this acquisition allows the Company to begin talks with its distribution network for exclusive opportunities within new verticals, providing an increase in revenues, profits, and financial stability with significant value to shareholders.
The acquisition facility, located in Santa Ana, the heart of Southern California, is a major transportation corridor. Currently, the facility produces semi-solid, liquid and topical products, holding more than 300 proprietary formulations. The current production capacity is 41,000 gallons per year, with additional room to expand to 160,000+ gallons per shift, per year within the same facility allowing for increased revenues and profitability.
"We look forward to welcoming our new partners and to building on our combined expertise in pharmaceutical manufacturing, stated Mr. Night. "We are incredibly proud of what our Company has accomplished and look forward to the next chapter."
About SOHM, Inc.: SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a vision "Globalè Prospèro" that tries to build continuous growth. SOHM manufacturing and marketing target the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India and a strategic alliance with US manufacturing facilities. Although SOHM's generic pharmaceuticals were exported globally and introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To learn more about SOHM, Inc., visit www.SOHM.com
Safe Harbor Statement:
This news release contains "forward-looking statements", which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on for the most recent fiscal year, our quarterly reports uploaded from time-to-time on OTCMarkets.com.
For more information, please contact:
SOHM, Inc.
www.SOHM.com
Tel: 714-522-6700
SOURCE: SOHM, Inc.
View source version on accesswire.com:
https://www.accesswire.com/672298/SOHM-Inc-Announces-Important-Details-of-Its-California-Pharmaceutical-Company-Acquisition-Expanding-Manufacturing-into-the-US-Market
FAQ
What is the significance of SOHM's acquisition of a California pharmaceutical company?
How much can SOHM's new facility produce after expansion?
What markets will SOHM target with the new manufacturing capabilities?
When was the press release regarding SOHM's acquisition published?
